Special Issue

Recent Advances in Ocular Drug Delivery

Message from the Guest Editors

Eye diseases are either treated with eye drops or, more rarely, systemically with intravitreal injections. However, the treatment efficacy of eye drops is low because only 1-5% of the administered drug remains in the eye long enough to be effective. For retinal diseases, this percentage drops down to less than 1% due to low ocular penetration. Therefore, repeated intravitreal injections are needed to treat retinal diseases, which can result in side effects and systemic spreading. Hence, more robust drug delivery systems need to be developed in order to avoid unwanted side effects and achieve better therapeutic outcomes. Nano- and microparticles offer great opportunities to overcome these challenges. This Special Issue aims to capture the current state-of-the-art advances in ocular drug delivery. Suggested topics include the following: novel micro- and nanoparticles: improvements in implantable devices and slow release systems; new approaches in targeted ocular drug delivery; and challenges and obstacles of ocular drug delivery (systems).

Guest Editors

Dr. Sven Schnichels

Centre for Ophthalmology, University Eye Hospital Tübingen, Tübingen, Germany

Dr. Miguel González-Andrades

- 1. Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital and University of Cordoba, 14004 Cordoba, Spain
- Department of Ophthalmology, Massachusetts Eye and Ear and Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114, USA

Deadline for manuscript submissions

closed (30 April 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/81288

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

